Bulk Pharmaceutical API Sources for ZALCITABINE

Bulk Pharmaceutical API Sources for ZALCITABINE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		JoCf@BYpR~QQJJZEKTNftuUUSHsl@@
Sigma-Aldrich		D5782_SIGMA
NIH Clinical Collection		SAM001246779
NovoSeek		24066
TCI (Tokyo Chemical Industry)		D3581
MolPort		MolPort-002-885-873

Bulk Active Pharmaceutical Ingredient (API) Sources for: Zalcitabine

Last updated: July 30, 2025

Introduction

Zalcitabine (2',3'-dideoxycytidine), a nucleoside analog reverse transcriptase inhibitor (NRTI), has historically been used in the management of HIV/AIDS. As a nucleoside reverse transcriptase inhibitor (NRTI), its efficacy depends heavily on the high purity and consistent quality of its active pharmaceutical ingredient (API). With advancements in HIV treatment and shifts in pharmaceutical manufacturing, sourcing reliable suppliers for Zalcitabine API remains critical for generic manufacturers, contract manufacturing organizations (CMOs), and research entities. This article examines global API sources for Zalcitabine, emphasizing supply dynamics, quality standards, regulatory considerations, and strategic procurement insights.

Global Landscape of Zalcitabine API Suppliers

Major Suppliers in Asia

Asian API manufacturers dominate the supply chain for many HIV drugs owing to their extensive infrastructure, cost advantages, and established compliance with international standards.

• China

  China remains the primary source of Zalcitabine API. Several Chinese pharmaceutical companies have developed capabilities to synthesize nucleoside analogs efficiently. Companies like Hubei Huishen Pharmaceutical Co., Ltd. and North China Pharmaceutical Group Corporation (NCPC) have historically supplied APIs for global markets, adhering to Good Manufacturing Practices (GMP) and meeting international quality standards.

• India

  Although less prominent than Chinese suppliers for Zalcitabine, India hosts firms with capabilities in nucleoside synthesis. Companies such as Divi's Laboratories and Gordon Life Sciences have demonstrated expertise in complex API manufacturing, although their focus has often been on more widely used HIV drugs like Lamivudine or Tenofovir.

Emerging Sources and Niche Suppliers

The niche API market often sees smaller, specialized manufacturers capable of producing limited quantities tailored to research or low-scale production. These suppliers may provide Zalcitabine API under strict quality controls or custom synthesis arrangements.

• Cuba and Brazil exhibit some capacity for HIV drug API production, largely due to their sustainable national HIV programs and broader biotech investments, though their API supply for Zalcitabine remains limited and predominantly used domestically.

Quality Standards and Regulatory Compliance

High-quality Zalcitabine API is essential for ensuring drug efficacy and safety, especially considering its critical role in antiretroviral therapy. Suppliers must demonstrate compliance with:

• GMP (Good Manufacturing Practices): Ensures consistent production quality aligned with global standards (FDA, EMA, WHO).
• Analytical Certification: Certificates of Analysis (CoA) confirming purity (>98%), residual solvents, heavy metals, and microbiological specifications.
• Regulatory Approvals: Suppliers with prior approval in major markets facilitate faster registration and minimized regulatory hurdles for end-product approval.

Most reputable suppliers list their APIs with regulatory authorities such as the US FDA or EMA, providing a verified compliance record that is vital for import approvals and market registration.

Procurement Challenges and Considerations

Sourcing Zalcitabine API faces several challenges:

• Limited Suppliers: Unlike more common HIV APIs, Zalcitabine has fewer manufacturers due to reduced demand following the advent of newer drugs with better safety profiles.
• Quality Assurance: Variability among suppliers necessitates rigorous due diligence, including audits, batch testing, and validation.
• Lead Times: API production, especially for complex nucleosides, can involve lengthy synthesis processes, affecting supply chain stability.
• Cost Factors: Prices vary depending on purity, supplier reputation, and quantity ordered. Chinese suppliers typically offer competitive pricing but may face scrutiny over quality assurances.
• Regulatory Barriers: Some suppliers may lack comprehensive regulatory documentation, complicating approval pathways, especially in strict markets.

Strategic Sourcing Recommendations

• Prioritize Suppliers with Regulatory Approvals: Choose suppliers with existing approvals (FDA, EMA, WHO) to streamline registration.
• Evaluate Quality Certifications: Confirm GMP compliance and detailed analytical reports before procurement.
• Build Long-term Relationships: Establish partnerships with reputable manufacturers to ensure reliability and supply continuity.
• Diversify Sourcing: Maintain relationships with multiple suppliers across regions to mitigate geopolitical or supply disruptions.
• Engage with Contract Manufacturing Organizations (CMOs): Consider CMOs capable of synthesizing Zalcitabine to scale production or tailor specifications.

Future Outlook and Market Trends

While Zalcitabine was once a key component of antiretroviral therapy, its use has declined with the development of newer agents with better pharmacokinetics and toxicity profiles. Nonetheless, in resource-limited settings or for research, reliable API supply remains essential. The global API market might see these sources consolidate or evolve with technological advancements in nucleoside synthesis.

Continued demand for generic HIV medications ensures sustained interest among regional suppliers, particularly in Asia. Suppliers with strict adherence to international quality standards and those with strong regulatory track records will remain preferred partners.

Conclusion

Reliable sources for Zalcitabine API are primarily located in China and, to a lesser extent, India and other emerging regions. Ensuring stringent quality, regulatory compliance, and supply chain resilience is crucial for pharmaceutical companies engaged in antiretroviral drug manufacturing. Strategic procurement, supplier validation, and sustained supplier relationships are pivotal for maintaining high-quality production and regulatory approval pathways.

---

Key Takeaways

1. Primary API sources for Zalcitabine are based in China, with emerging suppliers in India and other regions.
2. Regulatory compliance and GMP standards are critical in selecting reliable API suppliers.
3. Limited global supplier diversity underscores the importance of supply chain risk management.
4. Cost, quality, and regulatory validation should drive procurement strategies in sourcing Zalcitabine API.
5. Despite reduced use, demand from resource-limited settings sustains API supply channels for research and generics.

---

FAQs

1. Is Zalcitabine still widely available in the API market?
Zalcitabine's clinical use has declined significantly due to the development of newer antiretrovirals with better efficacy and safety profiles. Nonetheless, API availability persists mainly from Chinese and Indian manufacturers for research purposes and select generics, particularly in resource-limited settings.

2. What are the major quality concerns when sourcing Zalcitabine API?
The primary concerns include ensuring high purity (>98%), absence of residual solvents and heavy metals, and compliance with GMP standards. Verification through Certificates of Analysis and batch testing is essential before procurement.

3. How do regulatory standards influence API sourcing decisions?
Regulatory approvals or certifications from agencies like the FDA or EMA facilitate faster market registration, compliance, and confidence in supply quality. Suppliers with existing regulatory approvals reduce hurdles in clinical and commercial production.

4. What logistical considerations are involved in sourcing Zalcitabine API?
Lead times can be lengthy due to complex synthesis processes. Importation involves navigating tariffs, customs, and import regulations, especially in stringent jurisdictions. Establishing reliable logistics and supplier relationships ensures supply continuity.

5. Are there any emerging suppliers for Zalcitabine API?
Although some small or regional manufacturers may attempt to produce Zalcitabine, the market remains concentrated, and no significant emerging global suppliers have been reported recently. Continued demand driven mainly by resource-limited countries sustains existing supply channels.

---

References

[1] WHO Guidelines on Access to Antiretroviral Drugs. World Health Organization, 2020.
[2] U.S. Food and Drug Administration. Drug Master Files and API Manufacturer Listings.
[3] Pharmaceutical Technology. "Global API Manufacturing Overview." 2022.
[4] China State Food & Drug Administration. API Manufacturer Database.
[5] Indian Pharmaceutical Industry Reports, 2021.